Claims for Patent: 8,568,741

Summary for Patent: 8,568,741

Title:	Botulinum toxin for smoking cessation
Abstract:	The invention provides for the use of any form of botulinum toxin, or any enzymatically active derivative thereof, to cause temporary paralysis of the muscles of the lips of the mouth to promote smoking cessation.
Inventor(s):	Mehdi; Abbas (Fresno, CA)
Assignee:
Application Number:	13/410,017
Patent Claims:	1. A method for promoting smoking cessation, comprising administering an effective amount of a botulinum toxin, or an enzymatically active fragment thereof, to a muscle of the lips of the mouth of a subject in need thereof to inhibit the lips from forming a seal around a substantially cylindrical object 5 to 22 millimeters in diameter, thereby promoting smoking cessation, wherein the subject is not receiving and has not received a botulinum toxin at the muscle for the treatment of facial spasm or for cosmetic purposes. 2. The method of claim 1, wherein the substantially cylindrical object is a cigarette. 3. The method of claim 1, wherein the muscle of the lips is selected from the group consisting of orbicularis oris, mentalis, depressor labii oris, levator labii superioris, zygomaticus minor, and any combination thereof. 4. The method of claim 3, wherein the muscle of the lips is the orbicularis oris. 5. The method of claim 1, wherein the botulinum toxin is botulinum toxin A. 6. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of incobotulinumtoxinA, onabotulinumtoxinA, abobotulinumtoxinA, and a botulinum toxin consisting essentially of a botulinum toxin A having a molecular weight of 150 kDa. 7. The method of claim 1, wherein the effective amount is the amount required to produce the same maximum paralytic effect as 20 to 80 units of onabotulinumtoxinA. 8. The method of claim 1, wherein the botulinum toxin is onabotulinumtoxinA and the effective amount is 20 to 80 units. 9. The method of claim 1, wherein the botulinum toxin is incobotulinumtoxinA and the effective amount is 20 to 80 units. 10. The method of claim 1, wherein the botulinum toxin is abobotulinumtoxinA and the effective amount is 40 to 200 units. 11. The method of claim 1, wherein the botulinum toxin consists essentially of a botulinum toxin A having a molecular weight of 150 kDa and the effective amount is 20 to 120 units. 12. The method of claim 1, wherein the botulinum toxin is botulinum toxin B. 13. The method of claim 1, wherein the botulinum toxin is rimabotulinumtoxinB. 14. The method of claim 1, wherein the botulinum toxin is rimabotulinumtoxinB and the effective amount is 1000 to 8000 units. 15. The method of claim 1, wherein the administering comprises injecting the botulinum toxin at two or more sites. 16. The method of claim 1, wherein the subject is not receiving and has not received a botulinum toxin for the treatment of facial spasm or for cosmetic purposes. 17. The method of claim 1, wherein the effective amount of botulinum toxin, or enzymatically active fragment thereof, is administered to the orbicularis oris and mentalis muscles. 18. The method of claim 15, wherein at least one of the sites is at a corner of the mouth.

Details for Patent 8,568,741

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allergan, Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	12/09/1991		2039-03-29
Allergan, Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	12/09/1991		2039-03-29
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2039-03-29
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	04/29/2009		2039-03-29
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	07/30/2010		2039-03-29